"From evidence to practice" - Insights from the multidisciplinary team on the optimal integration of GLP-1 receptor agonists in obesity management services

Funding

AB has received research funding from the National Institute for Health and Care Research (NIHR), Medical Research Council (MRC), Rosetrees Trust, British Dietetic Association, BBSRC, Innovate UK, Public Health England and Novo Nordisk. AB reports honoraria from Novo Nordisk, Office of Health Improvement and Disparity, Johnson and Johnson and Obesity UK outside the submitted work and is on the Medical Advisory Board and shareholder of Reset Health Clinics Ltd. DM has received research funding and support from Innovate UK, National Institute for Health and Care Research (NIHR). DM reports honoria from ISA, WSRO, Danone and Mars along with consultancy work for British Dietetic Association. JM is funded by the NIHR and reports funding from the NIHR BRC and the Society for Endocrinology. JM reports institutional funding from Novo Nordisk, Rhythm Pharmaceuticals and Innovate UK outside the submitted work. ADM has received research funding from the Medical Research Council (MRC), National Institute for Health and Care Research (NIHR), Jon Moulton Charitable Foundation, Anabio, Fractyl, Boehringer Ingelheim, Gila, Randox and Novo Nordisk. ADM has received honoraria for lectures and presentations from Novo Nordisk, AstraZeneca, Currax Pharmaceuticals, Boehringer Ingelheim, Screen Health, GI Dynamics, Algorithm, Eli Lilly, Ethicon and Medtronic. ADM is a shareholders in the Beyond BMI clinic, which provides clinical obesity care. DJP has been funded by the Royal College of Surgeons of England. He receives consulting fees from Johnson & Johnson, Novo Nordisk, GSK and Pfizer and payments for lectures, presentations and educational events from Johnson & Johnson, Medtronic, Novo Nordisk and Sandoz. ES reports no conflicts of interest.